Background: COPD case finding is currently recommended at primary and tertiary care levels only.
Aim: To evaluate the feasibility of a community pharmacy program for COPD case finding in high-risk customers by means of spirometry.
Methods: Pilot cross-sectional descriptive study in 13 urban community pharmacies in Barcelona, Spain, from April to May 2007. Customers >40 years old with respiratory symptoms and/or a history of smoking were invited to participate in the study during pharmacists' routine work shifts. High-risk customers were identified by means of a 5-item COPD screening questionnaire based on criteria of the Global Initiative for Chronic Obstructive Lung Disease, and were invited to perform spirometry accordingly. Those with an FEV(1)/FVC ratio less than 0.70 were referred to the hospital for a repeat spirometry.
Results: Of the 161 pharmacy customers studied, 100 (62%) scored 3 or more items in the COPD screening questionnaire, and after spirometry, 21 (24%) had an FEV(1)/FVC ratio<0.7. When these subjects with airflow limitation were offered referral to a hospital respiratory function laboratory for further assessments, 11 (52%) attended the appointment. Over 70% of spirometries were rated as being of acceptable quality. No significant differences were observed in lung function parameters between the pharmacy and hospital measurements.
Conclusions: COPD case finding by spirometry in high-risk customers of urban community pharmacies is feasible. Similarly to primary care practitioners, pharmacists have access to high-risk, middle-aged subjects who have never been tested for COPD. Pharmacists can help with early detection of COPD if they are correctly trained.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.rmed.2008.12.022 | DOI Listing |
BMC Infect Dis
January 2025
The Third Department of Infection, Fifth Hospital of Shijiazhuang, Shijiazhuang, Hebei, China.
Background: The common diagnostic methods for tuberculosis have been showing reduced sensitivity among chronic obstructive pulmonary disease patients. This study was conducted to evaluate and analyse the diagnostic value of an interferon-γ release assay in COPD patients complicated with pulmonary tuberculosis.
Methods: A nested case-control study was conducted on 123 COPD patients hospitalized at the Fifth Hospital of Shijiazhuang, Hebei Province, from January 2019 to June 2021.
Am J Respir Crit Care Med
January 2025
Assistance Publique - Hopitaux de Paris, Department of Respiratory and Intensive Care Medicine, Paris, Île-de-France, France.
Ann Med
December 2025
Department of General Practice, Hainan affiliated Hospital of Hainan Medical University, Hainan General Hospital, Haikou, China.
Background: Although existing studies have identified some genetic loci associated with chronic obstructive pulmonary disease (COPD) susceptibility, many variants remain to be discovered. The aim of this study was to further explore the potential relationship between single nucleotide polymorphisms (SNPs) and COPD risk.
Methods: Nine hundred and ninety-six subjects were recruited (498 COPD cases and 498 healthy controls).
Front Med (Lausanne)
January 2025
Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Objective: The current study was designed with the aim of conducting a systematic review and meta-analysis to determine the circulating levels of visfatin in patients with chronic obstructive pulmonary disease (COPD) compared to healthy individuals.
Methods: Until March 2024, we searched the Web of Science, PubMed/Medline, and Scopus databases. The analysis included case-control studies assessing the association between circulating visfatin and COPD.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!